, Tracking Stock Market Picks
Enter Symbol:
Regeneron Pharmaceuticals, Inc. (REGN) [hlAlert]

down 22.32 %

Regeneron Pharmaceuticals, Inc. (REGN) downgraded to Hold with price target $525 by Canaccord Genuity

Posted on: Wednesday,  Jan 27, 2016  9:25 AM ET by Canaccord Genuity

Canaccord Genuity rated Hold Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on 01/27/2016. Previously Canaccord Genuity rated Buy Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on
08/05/2015., when the stock price was $592.80. Since then, Regeneron Pharmaceuticals, Inc. has lost 22.32% as of 01/27/2016's recent price of $460.46.
If you would have followed the previous Canaccord Genuity's recommendation on REGN, you would have lost 22.32% of your investment in 175 days.

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/27/2016 9:25 AM Hold
460.46 525.00
as of 8/27/2015
1 Week down  -7.08 %
1 Month up  3.25 %
3 Months up  9.47 %
1 YTD down  -9.24 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/5/2015 11:25 AM Buy
592.80 700.00
5/20/2015 10:25 AM Buy
513.47 600.00
5/8/2015 10:25 AM Buy
477.33 525.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy